Cost effectiveness of oseltamivir for the treatment of influenza in adults,adolescents and children in Finland

Summary

The objective of this study was to perform an economic assessment of the use of oseltamivir, compared with usual care, for the treatment of patients presenting with influenza-like illness in Finland. Three patient subpopulations were distinguished: (i) otherwise healthy adults; (ii) patients at risk; and (iii) children. The analyses were based on a decision analytic model populated with data specific for Finland and using first- and second-order Monte Carlo simulations. Probabilistic sensitivity analyses were performed to assess the impact of uncertainty regarding the most appropriate value for the variables and to derive cost-effectiveness acceptability curves in order to summarise the results. From a societal perspective, oseltamivir treatment was found to reduce costs in all groups. From a healthcare payer's perspective, improvements in outcomes were obtained at relatively modest incremental costs. The estimated incremental cost per day of normal activity gained was €27 in healthy adults, €8 in elderly and at-risk patients, and €14 in children.